TIVC earnings

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

Company advances its TLR5 agonist program and prepares to report VNS clinical data Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. "We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems," stated Tivic CEO Jennifer Ernst. "To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 793820 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/52776 About Tivic Health Systems, Inc. Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients' immune system. The company's

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. "This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Ernst. "In February, we executed a comprehensive worldwide exclusive licensing agreement for the Phase III TLR5 agonist, Entolimod and its molecular derivative, Ent

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID: 13753498 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1717125&tp_key=322c3ca4f6 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight

Pre-recorded Conference Call and Webcast to Follow Today at 1:30 PM PDT / 4:30 PM EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. "The important strategic events of the past several months have been nothing short of transformative," stated Tivic Health Chief Executive Officer, Jennifer Ernst. "We have successfully reshaped the company by expanding Tivic's opportunities in the biotech sector by in-licensing a late-stage biologic immunotherapy and advancing our ongoing work

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID Code: 13752399 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1711877&tp_key=ce7eaa5c39 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonom

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. "This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," stated Jennifer Ernst, CEO of Tivic Health. "The first prong is the aggressive steps we have taken to improve the economics of the ClearUP product line -- our comme

– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST - Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be submitted to ir@tivichealth.com by November 11. Conference Call Details: Toll Free: 877-545-0523 International: 973-528-0016 Access Code: 507355 Webcast Link

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a corporate update that will highlight the importance of Tivic's vagus nerve research program and its market potential. The company invites questions to be submitted to ir@tivichealth.com by August 11, 2024. Teleconference Details:

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q1 2024 financial results via pre-recorded conference call and webcast on Wednesday, May 15th at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 464810 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/50489 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures

Tivic Health® Systems, Inc. ("Tivic Health") (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its year-end financial results for 2023 via pre-recorded conference call and webcast on Monday, March 25, 2024 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 434944 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/50026 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus

71% Gross Profit Increase; 30% Decrease in Operating Expenses Tivic Health® Systems, Inc. (("Tivic", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 ("Q3 2023"). Third Quarter 2023 Financial Highlights Revenue for Q3 2023 was $282 thousand, compared to $161 thousand for Q2 2023 and $477 thousand in Q3 2022. Gross profit was $108 thousand, compared to $63 thousand in Q3 2022, an increase of 71%. Gross Margin of 38% in Q3 2023, compared to 13% in Q3 2022. Total operating expenses for Q3 2023 was $1.9 million, compared to $2.6 million for Q3 2022, a d

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the third quarter 2023 via pre-recorded conference call and webcast on Tuesday, November 14th, 2023 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 302318 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/49228 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, an

Tivic Health® Systems, Inc. (("Tivic", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter of 2023 ended June 30, 2023 ("Q2 2023"). Second Quarter 2023 Financial Summary Gross profit of 37.5% in the second quarter of 2023, compared to 23.4% in the second quarter of 2022, on total revenue of $60 thousand in the second quarter of 2023 from $123 thousand in the second quarter of 2022. Net loss of $2.1 million in the second quarter of 2023, compared with $3.0 million in the second quarter of 2022. Cash and cash equivalents totaled $2.7 million as of the quarter end. Second Quarter 2023

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter of 2023 via pre-recorded conference call and webcast on Monday, August 14th, 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll-Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 679005 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/48652 Shareholders also may submit questions in advance of the earnings call by sending them to the following email address - ir@tivichealth.com. The deadline for submitting questions in advance of the

Gross Profit Increase by 61.3%; extends innovation pipeline to include vagus nerve stimulation. Tivic Health® Systems, Inc. (("Tivic", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce its financial results for the first quarter of 2023 ended March 31, 2023 ("Q1 2023"). First Quarter 2023 Financial Summary Gross profit increased 61.3% to $113 thousand in the first quarter of 2023, compared with $70 thousand in the first quarter of 2022, on a decrease of 12% in total revenue to $376 thousand in the first quarter 2023 from $428 thousand in first quarter 2022. Net loss of $2.1 million in the first quarter of 2023, comp

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter 2023 via a pre-recorded conference call and webcast on Monday, May 15th, 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 888610 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/48259 Shareholders also may submit questions in advance of the earnings call by sending them to the following email address - ir@tivichealth.com. The deadline for submitting questions in advance of the webc

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2022. Year over Year Highlights 46% growth in revenue 114% growth in direct to consumer channels 9X improvement in gross margin Jennifer Ernst, CEO of Tivic Health, commented, "We executed our 2022 strategy of increasing our direct-to-consumer sales, reducing the overall manufacturing costs of ClearUP, and seeding our product pipeline. However, supply chain shortages, market volatility and economic uncertainty left us, along with others, with challenges

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the year ended December 31, 2022, via pre-recorded conference call and webcast on Friday, March 31, 2023, at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll-Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 990339 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/47805 Shareholders also may submit questions in advance of the earnings call by sending them to the following email address - ir@tivichealth.com. The deadline for submitting qu

65% growth in year-to-date revenue 146% increase in unit sales through direct-to-consumer channels for the same period Entered into definitive agreement to acquire Reliefband Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights (as compared to the same periods in 2021) For the three months ended September 30, 2022: Revenue increased 72% from $277 thousand to $477 thousand Direct-to-consumer unit sales volume increased 130% Gross Margin improved 22% For

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the third quarter of 2022 via conference call and webcast on Monday, November 14, 2022, at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll-Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 290242 Webcast Link: https://www.webcaster4.com/Webcast/Page/2865/46587 Shareholders also may submit questions in advance of the earnings call by sending them to the following email address - ir@tivichealth.com. The deadline for submitting questions in advance of the webcast/

Company Intends to Dramatically Expand Product Offerings into Bioelectronic Treatment of Nausea CEO to Host Investor Call/Webcast on Wednesday, October 19th at 1:30 PM PT / 4:30 PM ET  Tivic Health® Systems, Inc. (NASDAQ:TIVC) ("Tivic Health"), a commercial-phase health technology company focused on bioelectronic medicine, today announced it has entered into a definitive agreement to acquire the Reliefband product line for nausea treatment and all related assets from Reliefband Technologies, LLC. Reliefband has been an innovator in wearable, FDA-cleared electronic therapeutics for treatment of nausea and vomiting. Reliefband has multiple products available both over-the-counter and by p

265% growth in unit sales through direct-to-consumer channels, 97% overall revenue growth vs. Q2 2021 Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the quarter ended June 30, 2022. Jennifer Ernst, CEO of Tivic Health commented, "Our second quarter results demonstrate clear traction on the three pillars of the strategy we laid out last November – increasing direct-to-consumer revenue, reducing cost of goods and seeding our product pipeline." Q2 Financial Highlights 97% increase in revenue from $268 thousand in Q2 2021 to $528 thous

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the second quarter of 2022 via conference call and webcast, Monday, August 15, 2022, at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll-Free: 877-545-0320 International: 973-528-0002 Participant Access Code: 492379 Webcast Link: https://www.webcaster4.com/Webcast/Page/2865/46308 Shareholders also may submit questions in advance of the earnings call by sending them to the following email address - ir@tivichealth.com. The deadline for submitting questions in advance of the webcast/con

77% year-over-year growth in unit sales direct-to-consumer; 219% increase in gross profit. Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the quarter ended March 31, 2022. "I am pleased that our strategy to grow direct-to-consumer sales is driving both our revenue growth and increased gross margins. Increasing sales through direct-to-consumer channels is the first cornerstone in the strategic plan laid out by the company as part of its IPO last November," commented Jennifer Ernst, Tivic Health's CEO. "With a growing volume of unit sal

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter of 2022 via conference call and webcast, Monday, May 16, 2022, at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 535202 Webcast Link: https://www.webcaster4.com/Webcast/Page/2865/45466 About Tivic Health Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers a choice in the treatment of inflammation an

Tivic Health® Systems, Inc., (NASDAQ:TIVC) ("Tivic Health" or the "Company") a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that financial results for the fourth quarter of 2021 and the year-end shareholder update will take place via conference call on Tuesday, April 19, 2022, at 2:00 pm PT / 5:00 pm ET. Conference Call Information: April 19, 2022 at 2:00 pm PT / 5:00 pm ET Teleconference Toll-Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 689084 About Tivic Health Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that p